United States - English - NLM (National Library of Medicine)

galderma laboratories, l.p. - adapalene (unii: 1l4806j2qf) (adapalene - unii:1l4806j2qf), benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - adapalene 3 mg in 1 g - epiduo forte is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 12 years of age and older. epiduo forte is contraindicated in patients with a history of hypersensitivity reactions to benzoyl peroxide or any components of the formulation in epiduo forte. risk summary available pharmacovigilance data with epiduo forte use in pregnant women are insufficient to establish a drug associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with the combination gel. adapalene gel, 0.3% available data from clinical trials with adapalene gel 0.3% use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. in animal reproduction studies, oral administration of adapalene to pregnant rats and rabbits during organogenesis at dose exposures 41 and 81 times, respectively, the human exposure at the ma

United States - English - NLM (National Library of Medicine)

galderma laboratories, l.p - adapalene (unii: 1l4806j2qf) (adapalene - unii:1l4806j2qf) - adapalene 1 mg in 1 g - differin® cream is indicated for the topical treatment of acne vulgaris. differin® cream should not be administered to individuals who are hypersensitive to adapalene or any of the components in the cream vehicle.

United States - English - NLM (National Library of Medicine)

galderma laboratories, l.p. - adapalene (unii: 1l4806j2qf) (adapalene - unii:1l4806j2qf) - adapalene 0.1 g in 100 ml - differin lotion is indicated for the topical treatment of acne vulgaris in patients 12 years and older. differin lotion is contraindicated in patients who have known hypersensitivity to adapalene or any excipient of differin lotion [see warnings and precautions (5.1) ] risk summary available data from clinical trials with differin lotion use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. in animal reproduction studies, oral administration of adapalene to pregnant rats and rabbits during organogenesis at dose exposures 122 and 243 times, respectively, the human exposure at the maximum recommended human dose (mrhd) of 2 g resulted in fetal skeletal and visceral malformations (see data ). the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defects, loss, or other adverse outcomes. in the u.s. general popula

United States - English - NLM (National Library of Medicine)

a-s medication solutions - adapalene (unii: 1l4806j2qf) (adapalene - unii:1l4806j2qf) - adapalene gel, 0.1% is indicated for the topical treatment of acne vulgaris. adapalene should not be administered to individuals who are hypersensitive to adapalene or any of the components in the vehicle gel.

United States - English - NLM (National Library of Medicine)

mayne pharma commercial llc. - adapalene (unii: 1l4806j2qf) (adapalene - unii:1l4806j2qf) - adapalene gel is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. adapalene gel is contraindicated in patients who have known hypersensitivity to adapalene or any excipient of adapalene gel [see warnings and precautions (5.1)]. risk summary available data from clinical trials with adapalene gel use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. in animal reproduction studies, oral administration of adapalene to pregnant rats and rabbits during organogenesis at dose exposures 40 and 81 times, respectively, the human exposure at the maximum recommended human dose (mrhd) of 2 g resulted in fetal skeletal and visceral malformations (see data). the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defects, loss, or other adverse outcomes. in the u.s. general population the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 15 to 20%, respectively. data animal data no malformations were observed in rats treated with oral adapalene doses of 0.15 to 5.0 mg/kg/day, up to 8 times the mrhd based on a mg/m2 comparison. however, malformations were observed in rats and rabbits when treated with oral doses of 25 mg/kg/day adapalene (40 and 81 times the mrhd, respectively, based on a mg/m2 comparison). findings included cleft palate, microphthalmia, encephalocele, and skeletal abnormalities in rats and umbilical hernia, exophthalmos, and kidney and skeletal abnormalities in rabbits. dermal adapalene embryofetal development studies in rats and rabbits at doses up to 6.0 mg/kg/day (9.7 and 19.5 times the mrhd, respectively, based on a mg/m2 comparison) exhibited no fetotoxicity and only minimal increases in skeletal variations (supernumerary ribs in both species and delayed ossification in rabbits). risk summary there are no data on the presence of topical adapalene gel or its metabolite in human milk, the effects on the breastfed infant, or the effects on milk production. in animal studies, adapalene is present in rat milk with oral administration of the drug. when a drug is present in animal milk, it is likely that the drug will be present in human milk. it is possible that topical administration of large amounts of adapalene could result in sufficient systemic absorption to produce detectable quantities in human milk (see clinical considerations). the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for adapalene gel and any potential adverse effects on the breastfed child from adapalene gel, or from the underlying maternal condition. clinical considerations to minimize potential exposure to the breastfed infant via breastmilk, use adapalene gel on the smallest area of skin and for the shortest duration possible while breastfeeding. avoid application of adapalene gel to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child. safety and effectiveness have not been established in pediatric patients below the age of 12. clinical studies of adapalene gel did not include subjects 65 years of age and older to determine whether they respond differently than younger subjects. safety and effectiveness in geriatric patients age 65 and above have not been established.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - adapalene (unii: 1l4806j2qf) (adapalene - unii:1l4806j2qf) - adapalene 3 mg in 1 g - differin gel, 0.3% is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. differin gel, 0.3% should not be administered to individuals who are hypersensitive to adapalene or any of the components in the gel vehicle. teratogenic effects.  pregnancy category c. retinoids may cause fetal harm, when administered to pregnant women.  adapalene has been shown to be teratogenic in rats and rabbits when administered orally (see animal data below).  there are no adequate and well-controlled studies in pregnant women.  differin gel, 0.3% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.  the safety and efficacy of differin gel, 0.3% in pregnancy has not been established. human data in clinical trials involving differin gel, 0.3% in the treatment of acne vulgaris, women of child-bearing potential initiated treatment only after having had a negative pregnancy test and used effective birth control measures during therapy.  how

United States - English - NLM (National Library of Medicine)

galderma laboratories, l.p. - adapalene (unii: 1l4806j2qf) (adapalene - unii:1l4806j2qf) - adapalene 3 mg in 1 g - differin gel is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. differin gel is contraindicated in patients who have known hypersensitivity to adapalene or any excipient of differin gel [see warnings and precautions (5.1) ]. risk summary available data from clinical trials with differin gel use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. in animal reproduction studies, oral administration of adapalene to pregnant rats and rabbits during organogenesis at dose exposures 40 and 81 times, respectively, the human exposure at the maximum recommended human dose (mrhd) of 2 g resulted in fetal skeletal and visceral malformations (see data ). the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defects, loss, or other adverse outcomes. in the u.s. general population the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 15 to 20%, respectively. data animal data no malformations were observed in rats treated with oral adapalene doses of 0.15 to 5.0 mg/kg/day, up to 8 times the mrhd based on a mg/m² comparison. however, malformations were observed in rats and rabbits when treated with oral doses of ≥ 25 mg/kg/day adapalene (40 and 81 times the mrhd, respectively, based on a mg/m² comparison). findings included cleft palate, microphthalmia, encephalocele, and skeletal abnormalities in rats and umbilical hernia, exophthalmos, and kidney and skeletal abnormalities in rabbits. dermal adapalene embryofetal development studies in rats and rabbits at doses up to 6.0 mg/kg/day (9.7 and 19.5 times the mrhd, respectively, based on a mg/m2 comparison) exhibited no fetotoxicity and only minimal increases in skeletal variations (supernumerary ribs in both species and delayed ossification in rabbits). risk summary there are no data on the presence of topical adapalene gel or its metabolite in human milk, the effects on the breastfed infant, or the effects on milk production. in animal studies, adapalene is present in rat milk with oral administration of the drug. when a drug is present in animal milk, it is likely that the drug will be present in human milk. it is possible that topical administration of large amounts of adapalene could result in sufficient systemic absorption to produce detectable quantities in human milk (see clinical considerations ). the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for differin gel and any potential adverse effects on the breastfed child from differin gel, or from the underlying maternal condition. clinical considerations to minimize potential exposure to the breastfed infant via breastmilk, use differin gel on the smallest area of skin and for the shortest duration possible while breastfeeding. avoid application of differin gel to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child. safety and effectiveness have not been established in pediatric patients below the age of 12. clinical studies of differin gel did not include subjects 65 years of age and older to determine whether they respond differently than younger subjects. safety and effectiveness in geriatric patients age 65 and above have not been established.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - adapalene (unii: 1l4806j2qf) (adapalene - unii:1l4806j2qf) - adapalene 1 mg in 1 g - differin® cream is indicated for the topical treatment of acne vulgaris. differin® cream should not be administered to individuals who are hypersensitive to adapalene or any of the components in the cream vehicle.

United States - English - NLM (National Library of Medicine)

cvs pharmacy - adapalene (unii: 1l4806j2qf) (adapalene - unii:1l4806j2qf) - acne treatment - for the treatment of acne

United States - English - NLM (National Library of Medicine)

target corporation - adapalene (unii: 1l4806j2qf) (adapalene - unii:1l4806j2qf) - acne treatment - for the treatment of acne